News

Conference Coverage

Ripretinib for Patients With Advanced GISTs in Later-Line Therapy

02/24/2023

Allison Casey

In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.

In a multicenter, retrospective...

02/24/2023

Oncology

News

01/19/2023

Allison Casey

Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.

Among patients with rectal...

01/19/2023

Oncology

News

Avapritinib Shows Potential for Patients With PDGRFA D842V-Mutant Gastrointestinal Stromal Tumors

12/20/2022

Allison Casey

In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.

In a phase 1/2 study,...

12/20/2022

Oncology

News

Laparoscopic Surgery Demonstrates Feasibility, Safety for Gastrointestinal Stromal Tumors

11/17/2022

Allison Casey

Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.

Study findings reveal...

11/17/2022

Oncology

News

Guadecitabine Fails to Meet Target Response Rate in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumors

11/10/2022

Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.

Phase 2 trial results reveal...

11/10/2022

Oncology

News

Ripretinib Provides No PFS Benefit vs Sunitinib for Patients With Advanced Gastrointestinal Stromal Tumors

09/27/2022

Allison Casey

Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...

Second-line treatment with...

09/27/2022

Oncology

News

Trans-Anal Total Mesorectal Excision Technique Feasible for Rectal Gastrointestinal Stromal Tumors

09/20/2022

Allison Casey

In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.

In a retrospective study, the...

09/20/2022

Oncology

News

Comparison of Surgical Methods for Treating Gastrointestinal Stromal Tumors

08/04/2022

Allison Casey

Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.

Findings from a comparative...

08/04/2022

Oncology

News

Study Identifies Factors Associated With GIST Recurrence and Metastasis

08/03/2022

Allison Casey

Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.

Primary site of tumors, tumor...

08/03/2022

Oncology

News

Preoperative Controlling Nutritional Status Score Predicts Recurrence in Patients With Resected GIST

08/03/2022

Allison Casey

Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.

Study finds high preoperative...

08/03/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology